GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with annual revenues of $41.86 billion and an impressive gross profit margin of 72.39%, has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for Jemperli (dostarlimab) for treating patients with locally advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer.
According to InvestingPro analysis, GSK maintains a "GREAT" financial health score of 3.15, positioning it strongly for continued R&D investments. This designation is intended to speed up the development and review of drugs that could significantly improve treatment over existing options for serious conditions.
The Breakthrough Therapy Designation was granted based on the results from a phase II study showing a 100% clinical complete response rate in all 42 patients who completed treatment with dostarlimab. With GSK's stock currently trading at $33.76, InvestingPro analysis suggests the company is undervalued, presenting a potential opportunity for investors interested in companies with strong R&D pipelines.
For detailed valuation metrics and 8 additional exclusive ProTips, visit InvestingPro. This response rate is considered unprecedented, with no evidence of disease found in patients as assessed by various methods including magnetic resonance imaging and endoscopy.
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK, expressed that this designation supports their aim to change the treatment paradigm for patients with this type of cancer, who currently face long-term adverse effects on their quality of life due to the standard treatments involving surgery and chemoradiotherapy.
The ongoing phase II registrational AZUR-1 trial is further studying dostarlimab in this patient population, following the Fast Track designation received in January 2023. The safety profile of dostarlimab was reported to be consistent with its known profile, with no grade 3 or higher adverse events reported in the trial.
The current standard of care for dMMR/MSI-H locally advanced rectal cancer involves chemotherapy, radiation, and surgery, which can lead to significant long-term negative effects on quality of life. The Breakthrough Therapy Designation for dostarlimab offers hope for a treatment that could potentially avoid these adverse effects.
Dostarlimab is not yet approved for the treatment of locally advanced dMMR/MSI-H rectal cancer anywhere in the world. The ongoing studies aim to confirm the findings and potentially provide a new standard of care for this patient group.
Rectal cancer is the third most commonly diagnosed cancer globally, with dMMR/MSI-H cancers representing 5-10% of all cases. These cancers have abnormalities affecting DNA repair within the cells, which have been shown to predict response to PD-1 therapy. GSK's strong market position is reinforced by its 24-year track record of consistent dividend payments and robust cash flows.
InvestingPro's comprehensive research report provides in-depth analysis of GSK's market position and growth potential among 1,400+ top stocks, essential for understanding the company's long-term value proposition.
Jemperli is an anti-PD-1 antibody and forms the basis of GSK's immuno-oncology research and development. It is currently approved in the US for certain types of endometrial cancer and under accelerated approval for dMMR recurrent or advanced solid tumors, with continued approval contingent upon verification in confirmatory trials. This report is based on a press release statement from GSK plc.
In other recent news, GSK's cancer drug GSK'227 has been granted the PRIME status by the EMA, marking a significant step in the company's oncology development efforts. This follows the Breakthrough Therapy Designation it received from the US FDA earlier. Moreover, GSK's cancer drug Jemperli received a positive CHMP opinion for endometrial cancer, potentially broadening its usage for this type of cancer.
In a strategic partnership expansion, GSK extended its vaccine collaboration with Chongqing Zhifei Biological Products Co., Ltd in China until 2034, focusing on the commercialization of its shingles vaccine, Shingrix. GSK's respiratory syncytial virus vaccine, Arexvy, received extended approval in Japan for adults aged 50-59, expanding the demographic that can benefit from this vaccine.
However, financial analysts from Jefferies and Guggenheim have downgraded GSK's stock due to expectations of subdued growth in 2025. In related developments, HUTCHMED appointed a new independent non-executive director, contributing to the company's governance and strategic planning. These are some of the recent developments shaping the current landscape for GSK and HUTCHMED.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.